Baxter International (BAX)
(Delayed Data from NYSE)
$37.54 USD
+1.05 (2.88%)
Updated Aug 23, 2024 04:00 PM ET
After-Market: $37.40 -0.14 (-0.37%) 7:58 PM ET
3-Hold of 5 3
A Value F Growth C Momentum C VGM
We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies, revised Privacy Policy and Terms of Service.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
$37.54 USD
+1.05 (2.88%)
Updated Aug 23, 2024 04:00 PM ET
After-Market: $37.40 -0.14 (-0.37%) 7:58 PM ET
3-Hold of 5 3
A Value F Growth C Momentum C VGM
Zacks News
Headquartered in Deerfield, IL, Baxter International Inc. (BAX) is a global medical technology company. However, the company spun off its biopharmaceuticals segment into an independent entity – Baxalta Inc. Following the spinoff, the company consists of renal and hospital products, providing items such as kidney-dialysis equipment, infusion pumps, and intravenous (IV) solutions.
Baxter International (BAX) Earnings Expected to Grow: Should You Buy?
by Zacks Equity Research
Baxter (BAX) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
What's in Store for Intuitive Surgical's (ISRG) Q3 Earnings?
by Zacks Equity Research
Intuitive Surgical's (ISRG) third-quarter results are likely to reflect solid performance at the Instruments & Accessories segment.
How to Boost Your Portfolio with Top Medical Stocks Set to Beat Earnings
by Zacks Equity Research
Finding stocks expected to beat quarterly earnings estimates becomes an easier task with our Zacks Earnings ESP.
The Zacks Analyst Blog Highlights: Medtronic, Boston Scientific Corp, Catalent, Baxter International and Hill-Rom Holdings
by Zacks Equity Research
The Zacks Analyst Blog Highlights: Medtronic, Boston Scientific Corp, Catalent, Baxter International and Hill-Rom Holdings
MedTech Thrives on M&A Frenzy: 3 Stocks to Focus on
by Debanjana Dey
MedTech stocks like Boston Scientific (BSX), Catalent (CTLT) and Baxter (BAX) are likely to solidify businesses on the back of impressive M&As.
Baxter's (BAX) Premix Norepinephrine Now Available in U.S.
by Zacks Equity Research
Baxter's (BAX) norepinephrine can improve speed, efficiency and safety of treatment during critical care situations in hospital settings, and minimize compounding errors or touch contamination risks.
Baxter (BAX) to Benefit From Hill-Rom Buyout: Here's How
by Zacks Equity Research
Baxter's (BAX) latest acquisition is likely to accelerate its digitally-enabled connected care solutions across the care continuum and enhance patient services.
Hill-Rom (HRC) Agrees to Get Acquired by Baxter, Shares Jump
by Zacks Equity Research
The transaction is expected to close by early 2022 subject to the approval of Hill-Rom (HRC) shareholders and the fulfillment of customary closing conditions.
Baxter International (BAX) Q2 Earnings Surpass Estimates
by Zacks Equity Research
Baxter (BAX) delivered earnings and revenue surprises of 8.11% and -0.47%, respectively, for the quarter ended June 2021. Do the numbers hold clues to what lies ahead for the stock?
Baxter (BAX) Q2 Earnings Surpass Estimates, Revenues Miss
by Zacks Equity Research
Baxter's (BAX) second-quarter results reflect robust performance across all its business units.
Why the Earnings Surprise Streak Could Continue for Baxter (BAX)
by Zacks Equity Research
Baxter (BAX) has an impressive earnings surprise history and currently possesses the right combination of the two key ingredients for a likely beat in its next quarterly report.
DaVita (DVA) to Report Q2 Earnings: What's in the Offing?
by Zacks Equity Research
Sustained momentum with respect to U.S. dialysis revenue per treatment is likely to have aided DaVita's (DVA) top line in the second quarter despite ongoing pandemic-led higher PPE costs.
Baxter (BAX) to Report Q2 Earnings: What's in the Cards?
by Zacks Equity Research
Baxter's (BAX) second-quarter results are likely to reflect growth in its Acute Therapies business.
Baxter International (BAX) Earnings Expected to Grow: What to Know Ahead of Next Week's Release
by Zacks Equity Research
Baxter (BAX) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
3 Stocks in Focus on Evolving MedTech Trends Amid COVID-19
by Riya Anand
Stocks like Allscripts Healthcare Solutions (MDRX), National Vision Holdings (EYE) and Quest Diagnostics (DGX) are in focus on evolving MedTech trends.
Walgreens (WBA), VillageMD State 2021 Primary Healthcare Goal
by Zacks Equity Research
With this Walgreens (WBA) and VillageMD are on track to achieve their January 2021 goal of opening at least 600 Village Medical primary care practices in more than 30 U.S. markets over the next four years.
QIAGEN's (QGEN) NeuMoDx HAdV Quant Assay Wins CE-IVD Mark
by Zacks Equity Research
QIAGEN's (QGEN) NeuMoDx solutions at present offer CE-IVD tests for various viral and bacterial pathogens.
Amedisys' (AMED) VNA Assets Buyout Boosts Home Health-Hospice
by Zacks Equity Research
Leveraging on VNA's home health and hospice care legacy, Amedisys (AMED) expects to provide additional scale and resources.
Thermo Fisher (TMO) Introduces CoE in Clinical Metabolomics
by Zacks Equity Research
Thermo Fisher's (TMO) new research collaboration is aimed to provide the metabolomics community with advanced, best practices and standard operating procedures.
Here's Why You Should Retain AmerisourceBergen (ABC) Now
by Zacks Equity Research
AmerisourceBergen (ABC) continues to gain traction from robust pharmaceutical segment.
IDEXX Laboratories (IDXX) Hits 52-Week High: What's Driving It?
by Zacks Equity Research
Strong sales at the CAG and LPD arms are driving the top line for IDEXX Laboratories (IDXX).
Here's Why You Should Add STERIS (STE) to Your Portfolio
by Zacks Equity Research
Investors are optimistic about STERIS (STE) owing to strong segmental performance and bullish 2022 outlook.
QIAGEN (QGEN) Faces COVID-Support Sales Drop, Huge Debt
by Zacks Equity Research
With gradually falling COVID-19 cases, since the beginning of 2021, QIAGEN's (QGEN) COVID-19 testing related product lines are seeing significant decline in sales.
Surmodics (SRDX) Boosts Portfolio With Vetex Medical Buyout
by Zacks Equity Research
Surmodics' (SRDX) buyout of Vetex Medical adds second FDA 510 (k) cleared device to its thrombectomy platform.
Here's Why You Should Retain McKesson (MCK) Stock Right Now
by Zacks Equity Research
McKesson (MCK) continues to benefit from its robust Distribution Solutions segment.